The Oncotest™ Enables Physicians
Improve Therapy Selection To Deliver the Right Drug to the Right Patient
at the Right Time
Cancers
of
Unknown Origin
We collaborate with oncologists to select more effective treatments.
Overcoming Recurring Ovarian Cancer
Gyn-onc surgeons send patients' specimen for testing. The results of the SAGE Oncotest™ may provide new treatment options.
Avoiding Glioblastoma Resistance
Neurosurgeons send surgically removed tissue samples, to leverage our tumor resistance assay, the SAGE Oncotest™.
For
Late-Stage
Patients
When the course of treatment has failed,
leverage the full NCCN guidelines to find the needle in the haystack.
“Advance beyond standard of care within standard of care.”
How the Oncotest™ Works:
1
We create live 3D microtumors of the patient’s sample in a day...
2
that retain the microenvironment and heterogeneity of the sample...
3
testing multiple drugs using our proprietary technologies...
4
to identify the most effective therapy in just one week.
Non-Response to extremely high in vitro dosages predicts tumor resistance with increased accuracy
Testing Process
- The patient’s fresh sample is shipped overnight
- It is cultured with extremely high drug doses over 5 days
- It is labelled with T3-Thymidine
- The in vitro treatment effects are classified into 3 groups:
- Resistant (red): 0-40%
- Intermediate (gray): 40-80%
- Potentially Sensitive (green): >80%
Results
- If the effect of an extremely high drug dosage was less than 40%, none of the patients responded to the therapy.
- However, if the effect of an extremely high drug dosage was more than 80%, patients were most likely to respond, although it was not guaranteed.
Conclusion
- An extreme drug resistance assay can reliably predict tumor resistance but prediction on tumor sensitivity is less reliable.
